Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 26;14(8):e28426.
doi: 10.7759/cureus.28426. eCollection 2022 Aug.

Outcomes and Prognostic Factors of Metastatic Gastric Cancer: A Single-Center Experience

Mohamed Aseafan  1   2 , Ahmed Mostafa Gad  1   3 , Bader Alshamsan  1   4 , Naela Agha  1 , Ali Alhanash  5   6 , Ali H Aljubran  1 , Ahmed Alzahrani  1 , Shouki Bazarbashi  1
Affiliations

Outcomes and Prognostic Factors of Metastatic Gastric Cancer: A Single-Center Experience

Mohamed Aseafan et al. Cureus. .

Abstract

Background Gastric cancer (GC) carries a poor survival outcome despite the availability of many therapeutic agents active in treatment. In this study, we aimed to evaluate the survival outcomes of metastatic GC treatment from a single center in Saudi Arabia and identify possible prognostic factors. Methodology Data on patients diagnosed with metastatic GC between December 2009 and November 2013 were collected and analyzed. Results During this period, 41 patients were diagnosed with a median age at diagnosis of 52 years, and 56.1% of patients were males. Only four (9.2%) patients had human epidermal growth factor receptor 2 overexpression. Overall, 83% were treated with oxaliplatin-based chemotherapy. The median progression-free survival (PFS) and overall survival (OS) were 4.1 and 15.4 months, respectively. Female sex was an independent prognostic factor for better PFS and OS. Normal lymphocyte count was associated with improved PFS. Conclusions Our study highlights poor outcomes in patients with metastatic GC and the need for further research in this field.

Keywords: cancer survival; gastric cancer; gastroesophageal cancer; metastatic gastric cancer; progression-free survival.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Kaplan–Meier plots of (A) progression-free survival and (B) overall survival (OS) in patients treated for metastatic gastric cancer.
See this image and copyright information in PMC

References

    1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. CA Cancer J Clin. 2021;71:209–249. - PubMed
    1. Gastric cancer: epidemiology, biology, and prevention: a mini review. Lyons K, Le LC, Pham YT, et al. Eur J Cancer Prev. 2019;28:397–412. - PubMed
    1. Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity. Yang D, Hendifar A, Lenz C, et al. J Gastrointest Oncol. 2011;2:77–84. - PMC - PubMed
    1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Bang YJ, Van Cutsem E, Feyereislova A, et al. Lancet. 2010;376:687–697. - PubMed
    1. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Chung HC, Bang YJ, S Fuchs C, et al. Future Oncol. 2021;17:491–501. - PMC - PubMed

LinkOut - more resources